Zacks Research Downgrades SAB Biotherapeutics to Strong Sell

Analysts cite concerns over the company's financial performance and outlook

Mar. 14, 2026 at 11:07am

Got story updates? Submit your updates here. ›

SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biotechnology company focused on developing polyclonal antibody therapies, has been downgraded from a "hold" rating to a "strong sell" rating by analysts at Zacks Research. The downgrade comes amid concerns over the company's financial performance and future prospects.

Why it matters

The downgrade by Zacks Research, a prominent investment research firm, could negatively impact investor sentiment and the stock price of SAB Biotherapeutics. As a clinical-stage company, SAB's financial stability and growth potential are crucial factors for investors, and this downgrade may raise questions about the company's long-term viability.

The details

In their research note, Zacks analysts cited several factors that led to the downgrade, including weaker-than-expected financial results and a clouded outlook for the company's pipeline. The analysts also noted that other research firms have issued similar downgrades or sell ratings on SAB Biotherapeutics in recent months.

  • Zacks Research issued the downgrade on Thursday, March 14, 2026.

The players

Zacks Research

A leading investment research firm that provides analysis and recommendations on publicly traded companies.

SAB Biotherapeutics

A clinical-stage biotechnology company focused on developing polyclonal antibody therapies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The downgrade of SAB Biotherapeutics by Zacks Research highlights the challenges facing clinical-stage biotechnology companies in maintaining investor confidence and financial stability. As the company navigates its development pipeline, it will need to address the concerns raised by analysts to regain a more favorable rating and position itself for long-term success.